RLMD
Relmada Therapeutics, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| BCG-unresponsive patients complete response rate at 12 months | 80% | Phase 2a 12-month follow-up | — |
| BCG-unresponsive patients complete response rate at any time | 94% | Phase 2a 12-month follow-up | — |
| PIPE financing gross proceeds | $160M | March 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RLMD
this stock
Relmada Therapeutics, Inc.
|
$651.37M | +28.6% | -73.2% | — | 10.2% |
|
ONC
BeOne Medicines Ltd.
|
$439.30B | +0.0% | +22179.2% | 894.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.89B | +5.9% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.52B | -14.0% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.77B | +2.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RLMD | -3.1% | -6.6% | +57.6% | -10.3% | +28.6% |
| SPY | +0.6% | +1.4% | +11.0% | +0.7% | +10.3% |
| vs SPY | -3.7% | -8.0% | +46.7% | -10.9% | +18.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.